Skip to Content Facebook Feature Image

ALAR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Alarum Technologies (ALAR) Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Business

ALAR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Alarum Technologies (ALAR) Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Business

Business

ALAR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Alarum Technologies (ALAR) Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

2026-08-06 22:37 Last Updated At:22:41

NEW YORK--(BUSINESS WIRE)--Aug 6, 2026--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alarum Technologies Ltd. (“Alarum” or the “Company”) (NASDAQ: ALAR) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806582288/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) An Alarum Technologies subsidiary, NetNut, was engaging in illegal activity by linking customer home internet devices into another network without the customer’s consent; (2) This activity allows cyber criminals to conceal their locations; (3) The foregoing materially heightened Alarum Technologies’ legal exposure and materially threatened its business prospects; and (4) As a result, defendants’ statements about Alarum Technologies’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On July 2, 2026, after the market closed, Alarum issued a press release entitled "Alarum Technologies Responds to Inquiry into Residential Proxy Networks." The press release stated in part that on July 2, 2026, "Alarum and its subsidiary NetNut Ltd. (“NetNut”) were made aware of the seizure of certain domains associated with NetNut by the FBI."

On this news, Alarum American Depositary Shares fell 51.49% on July 6, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Alarum’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Alarum class action, go to www.faruqilaw.com/ALAR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Alarum Technologies Securities Class Action Lawsuit:

What is the Alarum Technologies securities fraud lawsuit about?

The lawsuit alleges Alarum Technologies misled investors by failing to disclose alleged unauthorized proxy network practices by its NetNut subsidiary and the resulting legal, regulatory, and business risks.

Who may be eligible to participate in the lawsuit?

Investors who purchased Alarum Technologies Ltd. (NASDAQ: ALAR) securities between March 20, 2025 and July 2, 2026 may be eligible to participate if they suffered losses.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by October 5, 2026. Investors may participate without serving as lead plaintiff.

What should investors do if they purchased Alarum Technologies stock during the Class Period?

Investors should review their trading records and consider consulting counsel about their legal rights, participation in the lawsuit, or seeking appointment as lead plaintiff.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Alarum Technologies securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

ALAR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Alarum Technologies (ALAR) Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

ALAR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Alarum Technologies (ALAR) Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

KYIV, Ukraine (AP) — Ukrainian soldier Mykola Kasiuk hopes to regain some vision after a battlefield land mine explosion left him nearly blind two years ago. After numerous operations, he is turning to visiting U.S. surgeons in Kyiv, hoping to see his children again.

Wounded soldier Mykola Kasiuk poses for a portrait ahead of surgery at a regional hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Wounded soldier Mykola Kasiuk poses for a portrait ahead of surgery at a regional hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

A medic leads wounded soldier Mykola Kasiuk, down a corridor at a regional hospital in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

A medic leads wounded soldier Mykola Kasiuk, down a corridor at a regional hospital in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Wounded soldier Artur Martosich, attends an appointment with an ocularist at the Imateh Medical laboratory in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Wounded soldier Artur Martosich, attends an appointment with an ocularist at the Imateh Medical laboratory in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Wounded soldier Artem Deresh poses for a photo before undergoing surgery at a regional hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Wounded soldier Artem Deresh poses for a photo before undergoing surgery at a regional hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Stuart Seiff, a U.S. oculoplastic surgeon, right, and a Ukrainian colleague perform a surgical operation on the eye of a wounded soldier at a regional hospital in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Stuart Seiff, a U.S. oculoplastic surgeon, right, and a Ukrainian colleague perform a surgical operation on the eye of a wounded soldier at a regional hospital in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Stuart Seiff, a U.S. oculoplastic surgeon, right, speaks to wounded soldier Mykola Kasiuk, after surgery at a hospital in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Stuart Seiff, a U.S. oculoplastic surgeon, right, speaks to wounded soldier Mykola Kasiuk, after surgery at a hospital in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Nurses transport wounded soldier Mykola Kasiuk, into a surgical unit at a hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Nurses transport wounded soldier Mykola Kasiuk, into a surgical unit at a hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Stuart Seiff, a U.S. oculoplastic surgeon, with Ukrainian colleagues perform surgery on the eye of wounded soldier Mykola Kasiuk at a hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Stuart Seiff, a U.S. oculoplastic surgeon, with Ukrainian colleagues perform surgery on the eye of wounded soldier Mykola Kasiuk at a hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Ocular prostheses are displayed on a table at the Imateh Medical laboratory in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Ocular prostheses are displayed on a table at the Imateh Medical laboratory in Kyiv, Ukraine, Tuesday, Sept. 29, 2026. (AP Photo/Evgeniy Maloletka)

Wounded soldier Mykola Kasiuk smiles as he poses for a photo ahead of surgery at a hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Wounded soldier Mykola Kasiuk smiles as he poses for a photo ahead of surgery at a hospital in Kyiv, Ukraine, Monday, Sept. 28, 2026. (AP Photo/Evgeniy Maloletka)

Recommended Articles